StockNews.com Initiates Coverage on Organovo (NASDAQ:ONVO)

Equities research analysts at StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a research report issued on Saturday. The firm set a “sell” rating on the medical research company’s stock.

Organovo Price Performance

Organovo stock opened at $1.03 on Friday. The firm has a market capitalization of $10.34 million, a P/E ratio of -0.47 and a beta of 0.87. The stock has a fifty day moving average price of $1.04 and a two-hundred day moving average price of $1.12. Organovo has a 52-week low of $0.89 and a 52-week high of $2.05.

Organovo (NASDAQ:ONVO) last announced its quarterly earnings results on Thursday, February 8th. The medical research company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.08 million. On average, equities research analysts predict that Organovo will post -1.74 EPS for the current fiscal year.

Organovo Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.